window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 11, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

ETH47

  • Advanced Therapies,Drug Discovery & Development,Opinion & Events

    Ethris begins Phase 2a trial of intranasal mRNA candidate ETH47 for virus-triggered asthma

    Ethris has dosed the first patient in a Phase 2a [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development

    Ethris secures €10 million EU4Health grant for ETH47 antiviral development

    Ethris GmbH has been awarded a €10 million grant from [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Alamar launches blood-based eMTBR-Tau assay for Alzheimer’s disease research
    Categories: Clinical & Regulatory, Medical devices, Research & Development, Therapeutic Areas
  • Bio-Rad launches Vericheck ddPCR kits for cell and gene therapy quality control
    Categories: Advanced Therapies, Manufacturing & Supply Chain, Medical devices, Research & Development
  • Genespire reports preclinical gene therapy data for methylmalonic acidemia
    Categories: Advanced Therapies, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top